Atara Biotherapeutics, Inc. (NASDAQ:ATRA) EVP Sells $20,604.36 in Stock

Atara Biotherapeutics, Inc. (NASDAQ:ATRAGet Rating) EVP Jakob Dupont sold 3,873 shares of the business’s stock in a transaction dated Tuesday, May 17th. The shares were sold at an average price of $5.32, for a total value of $20,604.36. Following the completion of the transaction, the executive vice president now directly owns 163,006 shares of the company’s stock, valued at approximately $867,191.92. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

Shares of NASDAQ:ATRA traded up $0.03 during midday trading on Thursday, hitting $5.16. 1,303,859 shares of the stock were exchanged, compared to its average volume of 1,011,949. The business’s 50-day moving average price is $7.92 and its 200 day moving average price is $12.85. Atara Biotherapeutics, Inc. has a 12 month low of $4.84 and a 12 month high of $20.04.

Atara Biotherapeutics (NASDAQ:ATRAGet Rating) last announced its earnings results on Thursday, May 5th. The biotechnology company reported ($0.87) EPS for the quarter, beating the consensus estimate of ($0.98) by $0.11. Atara Biotherapeutics had a negative return on equity of 113.94% and a negative net margin of 1,451.79%. During the same period in the previous year, the firm earned ($0.86) EPS. As a group, equities analysts forecast that Atara Biotherapeutics, Inc. will post -3.45 EPS for the current year.

A number of hedge funds have recently made changes to their positions in the stock. DekaBank Deutsche Girozentrale boosted its holdings in Atara Biotherapeutics by 2.9% in the fourth quarter. DekaBank Deutsche Girozentrale now owns 28,400 shares of the biotechnology company’s stock valued at $476,000 after acquiring an additional 800 shares during the last quarter. Rockefeller Capital Management L.P. lifted its stake in Atara Biotherapeutics by 2.4% in the fourth quarter. Rockefeller Capital Management L.P. now owns 38,916 shares of the biotechnology company’s stock valued at $613,000 after buying an additional 916 shares during the period. Swiss National Bank lifted its stake in Atara Biotherapeutics by 0.8% in the third quarter. Swiss National Bank now owns 157,900 shares of the biotechnology company’s stock valued at $2,826,000 after buying an additional 1,200 shares during the period. Cubist Systematic Strategies LLC lifted its stake in Atara Biotherapeutics by 7.3% in the fourth quarter. Cubist Systematic Strategies LLC now owns 18,823 shares of the biotechnology company’s stock valued at $297,000 after buying an additional 1,277 shares during the period. Finally, Teacher Retirement System of Texas lifted its stake in Atara Biotherapeutics by 12.6% in the first quarter. Teacher Retirement System of Texas now owns 15,447 shares of the biotechnology company’s stock valued at $144,000 after buying an additional 1,728 shares during the period.

A number of research firms have issued reports on ATRA. HC Wainwright reiterated a “buy” rating and issued a $31.00 target price on shares of Atara Biotherapeutics in a research report on Thursday, January 27th. StockNews.com cut Atara Biotherapeutics from a “hold” rating to a “sell” rating in a research report on Tuesday. Canaccord Genuity Group decreased their target price on Atara Biotherapeutics from $78.00 to $67.00 in a research report on Tuesday, March 1st. Citigroup cut Atara Biotherapeutics from a “buy” rating to a “neutral” rating and decreased their target price for the company from $15.00 to $8.00 in a research report on Monday, May 9th. Finally, JPMorgan Chase & Co. decreased their target price on Atara Biotherapeutics from $27.00 to $22.00 and set an “overweight” rating on the stock in a research report on Monday, March 28th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and four have assigned a buy rating to the company. According to MarketBeat, the company currently has an average rating of “Hold” and a consensus price target of $30.43.

About Atara Biotherapeutics (Get Rating)

Atara Biotherapeutics, Inc, an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. It is developing tabelecleucel, a T-cell immunotherapy that is Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as hematologic and solid tumors, including nasopharyngeal carcinoma.

See Also

Insider Buying and Selling by Quarter for Atara Biotherapeutics (NASDAQ:ATRA)

Receive News & Ratings for Atara Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atara Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.